| A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer F Zhao, E Olkhov-Mitsel, S Kamdar, R Jeyapala, J Garcia, R Hurst, ... Clinical epigenetics 10, 1-12, 2018 | 42 | 2018 |
| Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression S Kamdar, R Isserlin, T Van der Kwast, AR Zlotta, GD Bader, NE Fleshner, ... Clinical epigenetics 11, 1-19, 2019 | 30 | 2019 |
| Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis SN Kamdar, LT Ho, KJ Kron, R Isserlin, T van der Kwast, AR Zlotta, ... Clinical epigenetics 8, 1-17, 2016 | 27 | 2016 |
| An integrative DNA methylation model for improved prognostication of postsurgery recurrence and therapy in prostate cancer patients R Jeyapala, S Kamdar, E Olkhov-Mitsel, AJ Savio, F Zhao, C Cuizon, ... Urologic Oncology: Seminars and Original Investigations 38 (2), 39. e1-39. e9, 2020 | 14 | 2020 |
| GBX2 methylation is a novel prognostic biomarker and improves prediction of biochemical recurrence among patients with prostate cancer negative for intraductal carcinoma and … R Jeyapala, AJ Savio, E Olkhov-Mitsel, S Kamdar, F Zhao, C Cuizon, ... European urology oncology 2 (3), 231-238, 2019 | 12 | 2019 |
| Investigating urinary circular RNA biomarkers for improved detection of renal cell carcinoma MR Peter, F Zhao, R Jeyapala, S Kamdar, W Xu, C Hawkins, AJ Evans, ... Frontiers in oncology 11, 814228, 2022 | 9 | 2022 |
| Methylation markers in prostate biopsies are prognosticators for late biochemical recurrence and therapy after surgery in prostate cancer patients AJ Savio, S Kamdar, R Jeyapala, E Olkhov-Mitsel, C Cuizon, A Finelli, ... The Journal of Molecular Diagnostics 22 (1), 30-39, 2020 | 8 | 2020 |
| Integrative epigenomics of prostate cancer M Peter, S Kamdar, B Bapat Computational epigenetics and diseases, 247-263, 2019 | 4 | 2019 |
| A novel methylated cell-free DNA marker panel to monitor treatment response in metastatic prostate cancer MR Peter, M Bilenky, Y Shi, J Pu, S Kamdar, AR Hansen, NE Fleshner, ... Epigenomics 14 (13), 811-822, 2022 | 3 | 2022 |
| Combining CAPRA-S with tumor IDC/C features improves the prognostication of biochemical recurrence in prostate cancer patients R Jeyapala, S Kamdar, E Olkhov-Mitsel, A Zlotta, N Fleshner, T Visakorpi, ... Clinical Genitourinary Cancer 20 (3), e217-e226, 2022 | 3 | 2022 |
| A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence S Kamdar, NE Fleshner, B Bapat BMC cancer 20, 1-11, 2020 | 3 | 2020 |
| Exploring Targets of TET2-mediated Methylation Reprogramming as Potential Therapeutic Targets and Discriminators of Prostate Cancer Progression SN Kamdar University of Toronto (Canada), 2021 | | 2021 |
| Genome-wide integrative analysis correlating locus-specific DNA methylation and hydroxymethylation to gene expression in normal prostate cells SN Kamdar, LT Ho, R Isserlin, KJ Kron, T van der Kwast, AR Zlotta, ... CANCER RESEARCH 75 (22), 2015 | | 2015 |
| Abstract B1-32: Genome-wide integrative analysis correlating locus-specific DNA methylation and hydroxymethylation to gene expression in normal prostate cells SN Kamdar, LT Ho, R Isserlin, KJ Kron, T Kwast, AR Zlotta, NE Fleshner, ... Cancer Research 75 (22_Supplement_2), B1-32-B1-32, 2015 | | 2015 |
| hMeDIP-seq SN Kamdar, LT Ho, KJ Kron | | |
Neil FleshnerProfessor, university of TORONTOVerified email at utoronto.ca
